We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Halozyme Therapeutics Incorporated | NASDAQ:HALO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.52 | 1.32% | 39.82 | 37.13 | 42.69 | 40.74 | 38.88 | 39.56 | 832,175 | 01:00:00 |
Delaware | 88-0488686 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
11388 Sorrento Valley Road, San Diego, CA | 92121 | |
(Address of principal executive offices) | (Zip Code) |
Large accelerated filer ý | Accelerated filer ¨ | Non-accelerated filer ¨ | Smaller reporting company ¨ | |
(Do not check if a smaller reporting company) |
Item 6. | Exhibits |
31.1 | Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended | |
31.2 | Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended |
Halozyme Therapeutics, Inc., a Delaware corporation | |||
Dated: | August 11, 2015 | /s/ Helen I. Torley, M.B. Ch.B., M.R.C.P. | |
Helen I. Torley, M.B. Ch.B., M.R.C.P. President and Chief Executive Officer (Principal Executive Officer) | |||
Dated: | August 11, 2015 | /s/ Laurie D. Stelzer | |
Laurie D. Stelzer Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) | |||
1. | I have reviewed this Amendment No. 1 to Quarterly Report on Form 10-Q of Halozyme Therapeutics, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
Dated: | August 11, 2015 | /s/ Helen I. Torley, M.B. Ch.B., M.R.C.P. | ||||
Helen I. Torley, M.B. Ch.B., M.R.C.P | ||||||
President and Chief Executive Officer |
1. | I have reviewed this Amendment No. 1 to Quarterly Report on Form 10-Q of Halozyme Therapeutics, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
Dated: | August 11, 2015 | /s/ Laurie D. Stelzer | ||||
Laurie D. Stelzer | ||||||
Senior Vice President and Chief Financial Officer |
1 Year Halozyme Therapeutics Chart |
1 Month Halozyme Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions